Monoclonal antibodies have been a milestone in the treatment of multiple sclerosis (MS). Infective complications have been observed in patients on agents targeting lymphoid cells' surface antigens, namely anti-CD52 (alemtuzumab) and anti-CD20 agents (ocrelizumab and rituximab). Despite increasing emerging data, there is no standardized consensus regarding pre-treatment testing, vaccinations, and patient education before and during MS therapy or optimal infection-control strategies.
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis / Zappulo, Emanuela; Buonomo, Antonio Riccardo; Moccia, Marcello; Pinchera, Biagio; Villari, Riccardo; Petracca, Maria; Lanzillo, Roberta; Scotto, Riccardo; Carotenuto, Antonio; Viceconte, Giulio; Schiano Moriello, Nicola; Bruno, Luca; Gentile, Ivan; Brescia Morra, Vincenzo. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0356. - 63:(2022), p. 103814. [10.1016/j.msard.2022.103814]
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis
Zappulo, Emanuela;Buonomo, Antonio Riccardo;Moccia, Marcello;Pinchera, Biagio;Villari, Riccardo;Petracca, Maria;Lanzillo, Roberta;Scotto, Riccardo;Carotenuto, Antonio;Viceconte, Giulio;Schiano Moriello, Nicola;Bruno, Luca;Gentile, Ivan;Brescia Morra, Vincenzo
2022
Abstract
Monoclonal antibodies have been a milestone in the treatment of multiple sclerosis (MS). Infective complications have been observed in patients on agents targeting lymphoid cells' surface antigens, namely anti-CD52 (alemtuzumab) and anti-CD20 agents (ocrelizumab and rituximab). Despite increasing emerging data, there is no standardized consensus regarding pre-treatment testing, vaccinations, and patient education before and during MS therapy or optimal infection-control strategies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
